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Introduction 
Few would dispute that psychoanalytic practice has changed considerably over 
the last 50 years.  The differences are at least threefold: (a) a bimodal distribution 
of treatment lengths (some very long and some very short); (b) patients with 
personality pathology in addition to axis I symptoms; and (c) technical changes 
with a relational flavour, displaying influences from developmental theories 
including attachment theory.  Are any of these changes associated with scientific 
research, and if so, how? A second question concerns the research base of 
psychoanalysis.  If we take the discoveries of the last twenty five years seriously, 
what kind of therapy might we recommend to our patients?  Would it look 
anything like standard practice?  I will attempt to pose some serious questions 
about the status of clinical practice, asking why it appears to be protected from 
scientific advances yet readily responsive to pragmatic considerations such as 
third party payments.  To make the argument easier to absorb I will try and tell it 
as number of short heroic tales, each with its own beginning, middle and end 
complete with the moral lessons to be learned.   
 
The evidence base of psychotherapy in general 
I will begin with the story of the evidence base of psychotherapy in general.  This 
story began over half a century ago when an evil genius, a certain Dr Hans 
Eysenck (1952) disturbed the tranquility in the Kingdom of Psychotherapy 
established by a benign powerful ruler (Sigmund Freud, the Wise).  This evil 
genius made the claim that psychotherapy worked no better than the facility 
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nature gave all of us to recover from psychological disturbance by a process of 
spontaneous healing.  Up to that time, all the Templar Knights of psychotherapy, 
who were both fearsome warriors and devout monks, could righteously believe 
that the people they cured recovered because of their magic spells and carefully 
measured potions, which took often decades of apprenticeship to learn to brew 
with confidence.  This evil genius claimed that Sleeping Beauty woke up simply  
because she had slept long enough, and that her awakening had nothing to do 
with the magical time she spent on the couch.   
 
Fortunately, in raising this monster, he disturbed a nest of psychologists, who 
saw an opportunity to create a new hive for their worker bees (also called 
graduate students) and they called this psychotherapy research.  The researcher 
bees and their bee keepers went on to sample hundreds of thousands of therapy 
sessions and collected together a number of papers with magical powers, called 
an ‘evidence base’ which showed that the magic of psychotherapy was indeed 
magical.   
 
In the ensuing half a century the bee keepers and the researcher bees (the bee 
keepers actually looked more like Sancho Panza, and the templar knights a little 
like Don Quixote), demonstrated that the average EFFECT SIZE of 
psychotherapy was .8 across probably over 1,000 studies (Wampold, 2001).  
Effect size (ES) is researcher bee language for the likelihood that a person 
treated with psychotherapy magic would be better off than a person in the control 
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group if both were chosen at random (Cohen, 1962).  Using ESs the bees can 
collect together the nectar (the results) of hundreds of flowers (studies) and 
calculate the average ES for a treatment.  Tradition has it that an effect size of 
less than 0.3 is too close to the 50% mark (i.e. too close to chance), to call it a 
significant effect.  From 0.3 (where 58% of those treated are better off than 
untreated controls) to 0.6 (where 2/3 are better off) the effect is considered weak.  
From 0.6 to 0.9 (where ¾ of those treated are better than untreated controls) 
effect sizes are thought of as medium and beyond 0.9 we are in the land of 
strong effect sizes.  You should note that effect sizes are sometimes used to 
describe the change between the beginning and the end of a trial (pre-post effect 
size) and the difference between a treated and an untreated group at termination 
(between group effect size).  Pre-post effect sizes combine the effect of 
treatment with the monster that Eysenck raised – spontaneous remission.  One 
final note about the language of these researcher bees – in another of the 
dialects spoken in this evidence based magical beehive, differences are 
expressed in terms of the number of individuals who need to be treated before 
we come upon a person who unequivocally would not have got better on their 
own without the treatment (Laupacis, Sackett, & Roberts, 1988). 
 
So, 0.8 as a psychotherapy versus no therapy effect size is BIG -- in a moderate 
sort of way (Wampold, Imel, & Minami, 2007).  It means that nearly ¾ of patients 
who have psychotherapy are better off than those left to recover by themselves. 
The Number Needed to Treat (NNT) is 3.  As a marker, for those of you taking 
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aspirin as a prophylaxis for heart attacks, the NNT before you see one 
unequivocal case who benefitted is 129.  The effect size for Psychotherapy 
Magic is superior to almost all interventions in cardiology, geriatric medicine, 
asthma, flu vaccines, cataract surgery.  Psychotherapy is mostly as effective as 
psychoactive medication and there is evidence that additional benefit accrues 
from combining the magics in many contexts (e.g. Cuijpers, van Straten, van 
Oppen, & Andersson, 2008; Maina, Rosso, & Bogetto, 2009).   
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So this story appears to have a happy ending.  But like most of the stories that 
you will hear from me, and unlike real fairy stories, the ending is also curious and 
complex.  Effect sizes are inherently ambiguous.  A magical treatment could 
attain a moderate effect size by producing a very LARGE EFFECT for a SMALL 
SUBSET of patients or achieving a moderate but incomplete reduction in 
symptoms for many.  To clarify this, the researcher bees have collected data on 
the percent recovered or percent improved both by some predefined criterion.  
Two of the busiest beekeepers of psychotherapy research, Drew Westen and 
Elizabeth Bradley (Westen & Bradley, 2005), have provided us with an 
impressive meta-analysis of six disorders (MDD, panic disorder, GAD, OCD, 
bulimia nervosa and PTSD) based on percent improvers.  They tell a sobering 
tale.  Whilst across disorders, treatment versus control effect sizes tend to be 
moderate or large, on average only roughly half of patients who complete 
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treatments in these trials improve substantially.  The figures are even more 
sobering when we compute the percent of those who improved on the basis of all 
those who entered treatment.    On average, only 33% of those who entered 
treatment for depression can expect to improve significantly based on these 
figures.  A further surprise awaits us when we look at the percent who remain 
improved at follow-up.  Less than a third of those that complete treatment for 
bulimia remain improved.  But the figures for anxiety conditions (panic and GAD) 
tend to be better.   
 
Not surprisingly, improvement rates relate to severity and treatment duration 
(Kopta, Lueger, Saunders, & Howard, 1999).  On average, acute distress 
improves in ¾ of cases within 25 sessions.  But chronic disorders, defined in 
various ways, appear to require longer term treatment.  There is a less than 60% 
improvement rate after 25 sessions.  The situation is even worse for those who 
receive what we might refer to as a complex disorder diagnosis, that is, 3 or more 
diagnoses or diagnosis of a personality disorder.  Here improvement rates are 
less than 40% after 25 sessions.  There is even some indication, good magic 
turning bad, of inadvertent harm being done to patients with some personality 
disorders if they are offered time-limited treatment, so that they end up worse off 
than when they started (Tyrer et al., 2004).  The most recent German work from 
the bees in Horst Kaechele’s hive, a champion beekeeper of psychotherapy 
research, carefully following a group of patients with private health care 
insurance, reported that about one and a half years of treatment was required 
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before the average patient achieved an acceptable level of improvement 
(Puschner, Kraft, Kachele, & Kordy, 2007).  Incidentally, this work found no 
evidence for the much cited exponential rate of improvement originally 
demonstrated by Ken Howard (Howard, Kopta, Krause, & Orlinsky, 1986).  The 
relationship of improvement and time is best illustrated by a straight line.   
 
So what are the morals of the tale of psychotherapy in general?  Certainly there 
is good evidence for the efficacy of psychological therapies.  Over 1,000  
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studies demonstrate that in relation to major mental health conditions they can 
achieve significant symptom reductions and in some cases, particularly with 
anxiety disorders, freedom from symptoms.  The magic spell and potion, when 
appropriately administered, can improve social adjustment and work 
relationships.  However there are many different potions and some commonly 
used ones have been less well researched than others.  There is more evidence 
for the magic formula brewed by the knights of cognitive behaviour therapy than 
the potion generated in the cauldron of psychodynamic psychotherapy.  But of 
course, in practice most of those who brew these powerful mixtures combine 
several different recipes, and currently there is very little evidence for eclectic 
brews like these.  By contrast, researcher bees have been busy in relation to 
some little used concoctions, such as interpersonal psychotherapy.  There are 
 8 
also many diagnoses for which very little data has been collected, including 
eating disorders, bipolar disorder, and certain personality disorders such as 
avoidant PD.   
 
The story of long-term psychodynamic psychotherapy 
The next story is less epic and more recent than the previous one.  As with many 
modern stories, it is fraught with controversies and possibly insoluble problems.  
The beekeepers and researcher bees struggle to collect information about 
longer-term treatments to bring back to our collective knowledge base.  They 
found it hard to solve the problem of randomization when this involved getting 
agreement to go without the preferred treatment for 18 months or more.  Finding 
an appropriate control group was itself a challenge, as was the blinding of 
assessors, and the creating of manuals to guide work over a lengthy time period 
and ensure that what took place was what was described (treatment integrity).  
Yet for psychoanalytic clinicians this is the Holy Grail.  It is long term treatment 
that we have been trained to do and that we wish to make claims for.   
 
It is nothing short of miraculous that enough data have been collected for two 
prestigious systematic reviews to have been published, one by our friend Falk in 
the Journal of the American Medical Association,(Leichsenring & Rabung, 2008) 
and another by Askia de Maat and her colleagues in the Harvard Review of 
Psychiatry (de Maat, de Jonghe, Schoevers, & Dekker, 2009).  The latter review 
collected together 27 studies where the impact of long term therapy on symptom 
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reduction was measured, and/or information on personality changes was 
collected. The unmet challenge of the control groups meant that effect sizes were 
pre-post, not between-group.  Nevertheless, the studies covered the treatment of 
over 5,000 patients.  The effect sizes of outcome measures combined were 
between 0.8 and 1 and tended, if anything, to slightly increase on follow-up and 
were somewhat bigger for psychoanalysis than psychotherapy.  The percent 
success rate on symptoms was around 70% based on clinicians’ opinion and 
between 60-70% for patient self-report, when success was defined as at least 
moderate improvement.   
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The Leichsenring meta-analysis was very ambitious and identified 23 studies.  
The studies concerned difficult problems, but pre-post effect sizes were 
consistently large.  For chronic problems, the effect size is 0.87 - 2.45, for 
complex depression and anxiety it is 0.97-1.94, multiple problems 0.94-1.84, and 
personality disorder 0.82-1.65.  Controversially, the authors contrasted these 
effects with those normally obtained for similar client groups in short-term therapy 
and found a significant superiority for long term treatment.  The size of effects 
varied according to type of measure, with the largest effect sizes consistently 
obtained on target problems, and social and personality functioning coming some 
way behind.  However the effects were consistently positive, with the confidence 
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interval around the effect sizes comfortably above the line of insignificance, the 
dreaded 0 line.   
 
As you might imagine, not all in the Land of Psychotherapy Research were 
happy on hearing this news (Beck & Bhar, 2009; Glass, 2008; Kriston, Holzel, & 
Harter, 2009; Roepke & Renneberg, 2009; Thombs, Bassel, & Jewett, 2009) and 
the ensuing correspondence had the consistent theme of debunking positive 
evidence for long term treatment.  The details should perhaps be consigned to 
the history books, but the points raised address both the nature of the original 
studies (the review was based on studies with small samples with a likely bias 
towards the positive, treating a wide range of disorders with poorly specified 
control groups, and uncontrolled for contact and the structure of treatment) and 
the methodology of the review (conflating within-group and between-group effect 
sizes, selective inclusion and exclusion of studies etc).   
 
Our bards put up a spirited defense over several pages of the journal 
(Leichsenring & Rabung, 2009).  But the substance of the attacks was hard to 
deny.  Many of the studies reviewed were in effect uncontrolled and 
heterogeneous and it is hard to feel confident that the original critique by the Evil 
Genius, Hans Eysenck, was adequately addressed by the original collection of 
reports.  So the bards returned to their crypts and wrote a new ballad which is not 
yet published, and therefore I am only at liberty to share the refrain.  They 
identified 10 controlled studies of long term psychoanalytic psychotherapy versus 
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other types of treatment  (Bachar, Latzer, Kreitler, & Berry, 1999; Bateman & 
Fonagy, 1999; Bateman & Fonagy, in press; Clarkin, Levy, Lenzenweger, & 
Kernberg, 2007; Dare, Eisler, Russell, Treasure, & Dodge, 2001; Gregory et al., 
2008; Huber, Denscherz, Gastner, Henrich, & Klug, submitted; Korner, Gerull, 
Meares, & Stevenson, 2006; Svartberg, Stiles, & Seltzer, 2004) where these 
treatments were used in the treatment of complex disorders, chiefly personality 
disorder (7), eating disorders (2) and depression (1).  The comparisons are with 
CBT, DBT, CAT, SCM and TAU.  The treatments lasted on average 70 weeks 
offering 120 sessions.  The comparison treatments lasted about the same time, 
although offered fewer sessions.  The findings were similar to the previous 
analysis.  The average between-group effect  
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size was 0.67, somewhat larger for target problems, 0.88, than general 
psychiatric symptoms, 0.54.  Medium effect size differentiated the comparison 
groups from LTPP in terms of personality and social function.   
 
Why are these findings of enormous importance?  This is the first set of strong 
signals which suggests that long term psychodynamic psychotherapy is superior 
to less intensive treatments when directed towards complex mental disorders.  
No doubt when these findings are published there will be a chorus of complaints 
concerning the original studies and the methodology of the review.  But should 
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this surprise us?  We live in a competitive world.  What is good for 
psychodynamic therapy is often felt to disadvantage other orientations.  
Collectively, we have expressed dissatisfaction on many occasions about similar 
issues in relation to trials of CBT.   
 
Nevertheless, before concluding, let us once again draw the morals from our tale.  
First, whilst it is reassuring and helpful that LTPP knights struggle for longer and 
ultimately more effectively than the knights with other crests on their shields, we 
do not know how well the other knights would do if their rules of combat 
permitted them to battle as intensely and at as close a range as our knights did.  
Second, the knights indeed showed their valour in these most ardent of trials 
rescuing suicidal self-harming damsels in distress (both BPD and eating disorder 
samples are 80% female).  But how common are such challenges in our 
consulting rooms where we take the same amount of time, and sometimes 
longer, to rescue individuals of both genders, who perhaps at least superficially 
are in less distress?  Is the superiority of our knights still evident, and if so in 
what respect?  The study of private insurance cases I mentioned earlier 
(Puschner et al., 2007) would suggest caution.  When psychoanalytic 
psychotherapy and psychodynamic psychotherapy were tracked over two years 
in 480 patients no significant differences were seen in the rate or extent of 
decline between these two groups.  So, what is the moral?  We need more trials 
with a broader set of outcome measures.   
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Before closing my tale about LTPP, let me make three further observations; first 
on the naturalistic follow-up of patients treated by members of this organisation in 
long term therapy or psychoanalysis (Beutel, Rasting, Stuhr, Ruger, & Leuzinger-
Bohleber, 2004; Leuzinger-Bohleber, Stuhr, Ruger, & Beutel, 2003).  It was an 
interesting and carefully constructed study, not so much for the findings but 
because the Templar knights who offered the treatment worked alongside the 
researcher bees and used qualitative as well as quantitative methods to show 
how the patients experienced their treatment.  The vast majority of patients 
valued their experiences and the impact of treatment could be measured in terms 
of healthcare costs.  The most ambitious study of psychoanalytic psychotherapy 
comes from Helsinki (Knekt et al., 2008).  It contrasted Solution Focused 
Therapy and psychodynamic psychotherapy with long term psychodynamic 
psychotherapy for patients with mixed depression and anxiety problems.  These 
beekeepers and research bees worked extremely hard and pursued their 
patients relentlessly over three years.  This was just as well  
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because significant benefit from long term treatment was not found at 18 months, 
nor even at 24 months but only at 36 months.  In fact our knights, who had been 
trained to do battle for years rather than months, took their time to achieve 
success and were frankly struggling to keep up with the progress of their short 
term colleagues over the first year of the trial.  But of course it could be said that 
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the patients who selected themselves for long term treatment were the tougher 
customers.  The third study is probably the best study of LTPP so far carried out. 
The Munich study of Dorothea Huber and Gunter Klug (Huber et al., submitted) is 
remarkable for being the only one to use a specifically psychoanalytically 
oriented outcome measure, Wallerstein’s Scales of Psychologoical Functioning 
(Klug & Huber, 2009). The instrument is based on psychoanalytic experts’ 
definitions and includes 17 dimensions, each divided into 2 sub-dimensions, (a) 
exaggerated and (b) inhibited functioning.  So impulse regulation may be 
pathological because of over-indulgence or over-inhibition. You could finally see 
the benefits of psychoanalysis on this measure, but even here, convincingly only 
after a one year-wait.  
 
So, it seems to me that in looking at intensive long term treatment we are 
probably measuring the wrong things and not for long enough. 
 
The current story of psychotherapy for BPD: an example 
Before ending this part of my story and whilst I still have your attention, I would 
like to tell you one of my own tales. Indulge me please, not only because it is a 
story where I played the part of a beekeeper but because it illustrates a number 
of the issues of evidence with which we as knights of psychodynamic 
psychotherapy are having to confront.   
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Now, there has been many a trial with patients known as borderline and many a 
potion has been tried and shown to be effective in randomized controlled trials.  
These include DBT (e.g. Linehan et al., 2006), TFP (e.g. Clarkin et al., 2007), 
SFT (e.g. Giesen-Bloo et al., 2006), CBT (e.g. Cottraux et al., 2009), CAT (e.g. 
Chanen et al., 2008), DDP (e.g.Gregory et al., 2008), STP (e.g. Blum et al., 
2008) and MBT (e.g.Bateman & Fonagy, 2008).  It should be clear to you that as 
long as the acronym for the magic formula has three letters in it, it will be shown 
to be superior, mostly against treatment as usual or a less than adequate 
comparison.  All these treatments are specialist interventions requiring extensive 
training and continuous supervision.   
 
So, when Antony Bateman and I started out on our quest (Bateman & Fonagy, in 
press), we made solemn oaths that we were not going to return unless we found 
a comparison that was more meaningful to practitioners and third party payers 
than the comparisons we found in the journals kept by the High Priests of 
evidence based practice.  Our solemn oath committed us to find superiority  
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compared to a structured treatment organized in a coherent treatment 
programme with equivalent supervision, when both treatments were delivered by 
knights trained to the same level but without family crests committing them to one 
or other side.  We also swore to collect a clinically representative sample of 
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damsels and gentlemen with confirmed diagnosis of BPD and at high risk of 
suicide.  We swore not to stop until we reached adequate statistical power to 
detect even relatively small differences.   
 
Our quest concerned the trial of Mentalisation Based Treatment (Bateman & 
Fonagy, 2006), a potion we ourselves concocted containing special ingredients 
to help patients understand their mental states more clearly, both simple and 
complex, and assist them in regulating their emotions, focus their attention 
(effortful control) and conceptualise their own actions and the actions of others in 
terms of thoughts, feelings, wishes, beliefs and desires.  MBT is not concocted to 
make people ‘see in the dark’ (in other words it is not aimed at unconscious 
insight) but rather to help them to make better psychological sense of 
preconscious aspects of their interpersonal (especially their attachment) 
relationships, including their relationship with their therapist.   
 
The trial was open to women or men who made a suicide attempt or a life-
threatening act of self harm within the last six months and who carried a 
confirmed label of BPD.  Our commitment was to treat all comers to ensure that 
our potion worked for all, except those with organic brain disorder, psychotic 
disorder or opiate dependence.  We assessed patients at admission, six months, 
12 months and 18 months.  The programme lasted 18 months and included an 
individual and a group therapy session once per week.   
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Now, in order to ensure that it was our potion that was responsible for the healing 
and not our special knights with particular family crests, we co-opted 11 
apprentice knights who were randomly assigned to be trained to deliver 
outpatient MBT or outpatient structured clinical management (SCM). Structured 
clinical management is what a good psychiatric department should offer these 
patients in a coherent and ordered manner. All therapists had a minimum of 2 
years experience of treating patients in general psychiatric services following 
completion of their general psychiatric training and at least one year’s experience 
of treating patients with BPD.  Their average psychiatric experience was well 
over six years.  Amongst our knights were 7 nurses (4 MBT and 3 SCM), three 
trainee psychiatrists (2 MBT and 1 SCM) and one accredited counselor (SCM).  
We trained both the MBT and SCM therapists, and both trainings were carefully 
designed to be of roughly equal duration, 3 days basic training and 2 days 
advanced training for MBT and comparable basic training on personality 
disorders and generic supportive psychotherapeutic techniques for SCM.  
Supervision was offered on a weekly basis for the knights in both arms of the 
trial.   
 
SCM included many of the ingredients of MBT, including support and structure, 
challenging of self destructive acts, and crisis management, but in addition it 
included advocacy, social support work, problem solving and regular  
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medication reviews.  Knights trained in the MBT methods were taught how to 
enhance basic mentalising skills, how to offer mentalising interpretations, how to 
mentalize the transference, how to deal with crises, emotional storms, self-
harming behavior and suicide attempts by addressing these experiences as 
failures of mentalising triggered by a variety of interpersonal experiences.  The 
medication review for this group followed the same protocol as the SCM group, 
but the therapist knights were required to attempt to explore the psychological 
reasons behind the requests by the patients or others involved with the patients 
for changes in medication, in the same way as they would for all the patient’s 
other actions.   
 
168 patients were screened for eligibility and 134 were randomized.  Of the 
patients excluded, 1/3 did not attend interviews and a further 1/3 declined 
participation.  The rest either did not meet inclusion or exclusion criteria or were 
uncontactable.  52 of 71 participants allocated to MBT completed treatment and 
47 out of 63 allocated to SCM did so.  There was minimal missing data and all 
allocated patients were included in the analysis.  The primary outcome was the 
proportion of each group without severe para-suicidal behavior as indicated by 
suicide attempts, life-threatening self-harm or hospital admission in the previous 
6 months.  The randomization was successful and the groups did not differ in key 
characteristics.  This was a fairly complex group of patients with about 3 Axis I 
diagnoses and 2.5 Axis II diagnoses in addition to BPD.  By 18 months 57% of 
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the SCM group but only 27% of the MBT group had shown severe parasuicidal 
behavior, which corresponds to a relative risk reduction of 0.46 and an NNT of 
three.  Breaking this down into suicide attempts, life threatening self-harm and 
hospital admission separately, we find significant benefits for suicide (NNT of 4), 
hospitalization (NNT of 6) and a somewhat less convincing effect for self harm 
(NNT of 5 but CI of 2-32).  At the end of the 18 months was over 70% in the MBT 
group but only 45% in the SCM group were no longer taking psychoactive 
medication.   
 
I don’t have time to recount all the results but self-report measures of symptom 
severity, depression, social adjustment and interpersonal problems as well as 
blind ratings of general adaptive functioning (GAF) scores suggested that MBT 
benefitted patients substantially more than SCM.   
 
However, an important moral of this tale for us was less how well the knights 
wearing MBT colours did and more how well both groups did on almost all the 
measures.  Whilst our treatment may have worked better, both structured 
integrated and focused treatment protocols achieved better results than we might 
expect from spontaneous remissions of symptoms from follow-along studies.  So, 
while the trial supported MBT, it also supported structured treatment approaches 
in general.  The general utility of focusing on the patient’s mind is supported and 
the trial strongly contraindicated the adoption of non-focused generic approaches 
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and the premature exclusive adaptation of any one model.  We shall return to this 
theme later on. 
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The story of the demise of the randomized controlled trial 
I think it is now time to recount the stories of the sect of zealots who have tried to 
rule the kingdom of psychotherapy over the last couple of decades (Sackett, 
Richardson, Rosenberg, & Haynes, 2000; Strauss, Richardson, Glasziou, & 
Haynes, 2005).  They wear many crests on their shields, but all swear allegiance 
to evidence based medicine as “the conscientious explicit and judicious use of 
current best evidence in making decisions about the care of individual patients” 
(Sackett, Rosenberg, Gray, Haynes, & Richardson, 1996).  Their slogans are 
motivational, persuasive and essentialist rather than reportive, stipulative and 
operational.   
 
The initiative is basically synonymous with attempts experimentally to establish a 
causal relationship between treatment and outcome.  Hence their most highly 
valued strategy is the randomized controlled trial.  Now, a strange thing 
happened last year.  A high priest of evidence based medicine, none other than 
Sir Michael Rawlins, the Director of the National Institute of Health and Clinical 
Excellence (NICE), gave a Harveian Oration at the Royal College of Physicians 
about the over-valuation of randomized controlled trials in evidence-based 
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medicine (Rawlins, 2008).  He pointed out that frequently such trials are 
inappropriate.  There can be bioethical and legal problems in randomizing people 
to ineffective or harmful treatments.  Some conditions are so rare and some 
treatment effects so massive that few would consider RCTs to be sensible.  For 
example, parachutes are very widely used despite the fact that they have not 
been subjected to RCTs.  He also pointed out that the null hypothesis of RCTs 
was there often for show rather than genuine conviction.  It was certainly 
inappropriate where previous studies had already shown an effect and 
statistically and conceptually difficult if the aim of the study was to show no 
difference between treatment arms.  Rawlins also identified some challenges in 
relation to applying theories of probability in RCTs.   
 
Many studies use multiple variables to measure outcome, and this has massive 
potential to create confusion.  With Anna Higgitt we have made a study of 
reviews of the value of SSRIs for paediatric depression (Fonagy & Higgitt, 2009).  
There are only about 15 RCTs but nearly 100 reviews have been published since 
2005.  These review the same investigations but come to dramatically different 
conclusions by focusing on different aspects of the results reported in the original 
investigations.  The conclusions vary anywhere between ‘ban all SSRIs’ to ‘use 
SSRIs as first line of treatment’ with various gradations in between.  (‘Ban some 
SSRIs’, ‘use only one in first line treatment’, ‘use as second line treatment after 
psychological therapy has failed’, etc.)   
 
 22 
Sir Michael went on to revisit the issue most frequently alluded to in considering 
the appropriateness of RCTs in the Kingdom of Psychotherapy: how 
generalisable are the results of RCTs?  Certainly, the settings in which 
psychotherapy RCTs take place are quite different from the real clinical situation  
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(La Greca, Silverman, & Lochman, 2009; Weiss, Guidi, & Fava, 2009).  Most are 
undertaken in selected populations for a finite time, rather than a heterogeneous 
population with many life problems and co-morbidities which might exclude them 
or they would exclude themselves.  Certainly patients in trials and ‘real life’ differ 
in age, gender, severity, risk factors, co-morbidities, ethnicity, socio-economic 
status.  As if that was not bad enough, the treatment given in psychotherapy 
RCTs rarely fits clinical reality in terms of dose (frequency of therapy), timing of 
administration, duration of therapy, inter-current treatments, the skills and 
commitment of the practitioners.  There are major differences in the setting, the 
way the treaters are reimbursed, and their professional priorities – publication 
versus clinical care.  There is a real question about whether the assessment of 
benefit obtained from a trial can be applied to ordinary clinical settings.   
 
Sir Michael also drew attention to the assessment of harm.  RCTs are appalling 
at testing for the possibility of harm (e.g. Lilienfeld, 2007; Roback, 2000).  
Jeffreys et al (Jefferys, Leakey, Lewis, Payne, & Rawlins, 1998) noted that 
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surveying drugs introduced between 1972 and 1994, they could find 22 that were 
withdrawn for safety reasons but only one withdrawn for lack of efficacy.  This is 
hardly surprising, since RCTs are rarely powered up to scrutinize adverse 
events.  The controversy over SSRIs and paediatric suicide is a good example.  
None of the placebo-controlled trials are large enough to show a significant 
difference in rates of spontaneous adverse events (SAEs).  When taken together, 
they showed such events to be twice as frequent amongst children and 
adolescents taking active medication rather than placebo.  But then those 
advocating for the use of these drugs argue that the study designs and samples 
are too heterogeneous to permit that kind of integration.  
 
So perhaps, as Rawlins concluded, the knights of RCTs have been 
inappropriately elevated above those conducting observational studies.  The 
hierarchy is illusory.  Both kinds of study have advantages and disadvantages.  
In making decisions about cost-effective treatments against a background of 
limited resources, we need to appraise all the evidence and exercise judgment.  
RCTs are enormously costly.  153 pharmaceutical RCTs had median costs of 
£3,200,00, with an interquartile range of £2m - £6.25m.   
 
RCTs are not only resource intensive in terms of money – they also take up 
considerable time and energy.  Perhaps it is for this reason that their reporting is 
so often troubled by bias, aiming to emphasize the differences and be relatively 
silent about null findings.  Take just one recent example on therapy for treatment 
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resistant depression in adolescents (Brent et al., 2008).  Reading the abstract of 
this study we learn that when a young person did not respond to at least one 
SSRI, 40% are likely to improve if offered a medication switch. But they will 
improve even more if this switch is accompanied by CBT.  The response rate 
increase is 15%.  It makes no difference if they are switched to another SSRI or 
venlafaxine, but adding a psychological treatment clearly improves response 
rate.  I don’t want to bother you with the detail of this very complicated study 
other than to say that  
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a disturbingly large number of young people withdrew from each arm of the 
treatment (out of 334 randomised, 102 – almost 1/3 – withdrew from the 
treatment, a significant number (41) because of adverse events).  This raises real 
concerns about the acceptability of any of the treatment arms.  Looking at 
responders, it seems clear that adding CBT improved response rates, although 
this seems less clear when we look at only those young people who completed 
the treatment trial (i.e. had the full benefit of CBT).   
 
The story here is about something else, far more serious in relation to EBM. It is 
about three figures which I drew on the basis of numbers reported in very large, 
hard to access tables in the journal.  These concerned children’s self report of 
depression, suicidal ideation and the global assessment of independent 
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observers.  I challenge you to see any difference whatsoever between the 
severity of depression, suicidal ideation or even the probably not so blind 
assessors’ rating of global functioning.  The conclusion reported in JAMA is that 
the combination of CBT and a switch to another antidepressant results in ‘a 
higher rate of clinical response than did medication switch alone’.  In the body of 
the paper, which is all about the value of CBT for this group, there is a telling 
sentence: “There were no differential treatment effects on scalar measures of 
depression, suicidal ideation, and functioning, nor were there treatment effects 
on suicide attempts, or self-harm-related measures” 
 
I could bring many other similar examples of biased reporting of results.  They 
are more common in the pharmacological literature, where commercial interests 
are great, but they are by no means unique to them.  Nor would I wish to suggest 
that psychodynamic researchers are any less hampered by self serving biases 
than those from other orientations.  Fifteen years ago one of our champion 
researchers, Lester Luborsky (1999) published an entertaining paper that 
showed you could magically divine the conclusion of a paper on 
psychotherapeutic outcome just by knowing the theoretical orientation of its first 
author.  My point here is that notwithstanding the rhetoric of evidence based 
medicine, conscientious, explicit and judicious it frequently is not.  As 
psychoanalysts we understand about how the mind has ways of bending reality 
to that which maximizes pleasure and minimizes psychic pain.  Why should those 
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energetically in pursuit of making conscientious explicit and judicious use of 
current evidence be any different from the rest of us?   
 
I don’t have time to tell you the heroic tale of those who forced drug companies to 
reveal trial data indicating the risks of SSRIs, venlafaxine, mirtazapine etc.   Let it 
suffice to say that when five years ago we published data including unpublished 
studies along with published ones on the efficacy of SSRIs for paediatric 
populations we found a disappointing reduction in effectiveness (Whittington et 
al., 2004).  It took another four years before someone replicated our design for 
adult trial data (Turner, Matthews, Linardatos, Tell, & Rosenthal, 2008).  37 of 38 
studies viewed by the FDA as having positive results were published.  Out of 34 
studies viewed by the FDA as having negative  
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or questionable results, 22 were not published and 11 were published in a way 
that implied a positive outcome.  Conscientious? Explicit? Judicious? 
 
So, let’s turn over a metaphoric page.  The moral has to be: “read carefully, don’t 
believe everything you do read and look for things that could and should be 
there”.   
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A new intellectual framework for psychoanalytic psychotherapy research 
This brings me to the last of my tales.  This is a story of looking back towards the 
future - the title of a brilliant paper by my friends and colleagues Patrick Luyten 
and Sidney Blatt (Luyten & Blatt, 2007).   
 
There are a number of episodes to this story and the first concerns the question 
‘how do we know if we have won?’   
 
It turns out that our brave knights and their faithful researcher companions were 
competing in trials where not only the rules of engagement but also the criteria 
for winning had been defined by the Barons of Big Pharma.  The outcome 
measures in the field of psychotherapy are self-report measures designed to be 
reactive to changes which neuro-chemical interventions tend to bring, by and 
large the blunting of awareness of distress caused by symptoms.  Firstly, in many 
instances psychodynamic psychotherapy tries to increase awareness of distress 
rather than reduce it.  Second, it is a devastating indictment of the entire system 
that there has been almost no client participation in defining outcome measures 
and the entire scheme is an edifice to evidence based practice as prescribed by 
professionals (Dolan, Lee, King, & Metclalfe, 2009).  From a professional’s 
standpoint as from that of the ordinary member of the public, physical role 
limitation, physical function and pain have high priority, whilst those suffering 
disorders rate dignity and general wellbeing (mood, global assessment of life, 
having a partner, job, lots of social contact) as more important.  Wellbeing should 
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feature at least alongside, if not in place of, lists of symptoms in outcome studies 
(Pressman & Cohen, 2005). 
 
Measures for the most part are arbitrary, measuring subtle psychological 
processes on arbitrary scales.  Measures are arbitrary, but we reify them, we 
treat them and think of them as if they were not (Kazdin, 2006).  A review of 
2,000 RCTs in schizophrenia identified 640 scales, many of which were devised 
for the particular RCT and had no supporting data for validity or reliability.  
Unvalidated scales were more likely to show significant treatment effects than 
established scales. Arbitrary or not, our measures should be neutral in relation to 
the nature of treatment they intend to evaluate, otherwise we might find 
treatments targeting the scales of measurement rather than the disease process, 
which of course would be a travesty.  For a number of years we have had non-
reactive functional brain imaging measures of outcome available.  Since 
Eisenberger and colleagues (Eisenberger, Lieberman, & Williams, 2003) 
demonstrated that social exclusion could activate the very same brain areas 
(anterior cingulated cortex, right ventral pre-frontal cortex) as the experience of 
physical pain, there have been literally hundreds of demonstrations  
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of fMRI yielding accurate sensitive information related to subjective states.  There 
have been 27 neuro-imaging studies of psychotherapy using a number of 
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imaging modalities, a range of diagnoses and therapeutic approaches (Carrig, 
Kolden, & Strauman, 2009).   
 
These studies have their limitations, and almost no studies provide data on 
changes whilst treatment is going on.  However, with a little ingenuity from the 
beekeepers and researcher bees, functional tasks could be designed which are 
specific not only to the disease condition but also to the hypothesized 
mechanism of action of the mode of therapy.  Exploring the interplay of biological 
and psychological processes has the potential to enhance our understanding of 
the mode of action of psychotherapy.  Multiple lines of evidence are likely to be 
needed to identify the mechanisms critical to particular types of intervention 
(Kazdin, 2008).  The aim of this would not be to make psychological accounts 
redundant by providing a biological explanation, but rather to be more specific 
about what makes therapy work and to identify instances when it works well and 
for the long term.  Biomarkers of change offer a way to dig deeper than 
information on symptom distress.  Furthermore, basic biological research may 
suggest antecedents and primary pathologies that could prove to be targets for 
psychotherapeutic intervention.  For example, neuro-biological researchers have 
identified impulsivity as a key target for preventative intervention for problems of 
addiction (Lejuez et al., 2007).   
 
This brings us to one of the key questions facing our valiant knights as they look 
back into the future.  The system of feudal patronage without primogeniture 
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which dominates our psychotherapeutic kingdom has led to fragmentation; once 
vast fiefdoms have been reduced to literally hundreds of pocket-sized plots of 
land.  There are hundreds of therapies, many of them even possessing ‘title-
deeds’ (evidence) supporting their potential to produce change.  But are there 
really as many mechanisms for therapeutic change as there are modalities and 
orientations within modalities?  Understanding how psychotherapy leads to 
change could group these together.   
 
Are we as good at bringing about change as we think?  Have all these knightly 
trials of therapy improved our effectiveness as therapists?  Let me show you just 
one example.  These are the effect sizes obtained in trials of cognitive behaviour 
therapy from 27 trials in youth depression.  It should be obvious that rather than 
increasing in effect, the size of therapeutic benefit has been decreasing with time 
(Weisz, McCarty, & Valeri, 2006).  Why? The obvious answer is that the Templar 
Knights of therapy have given the wrong instructions to their researcher bees.  
Using increasingly stringent criteria to define a therapy that works (for example 
increasingly realistic tests of effectiveness) will not yield a more efficacious 
treatment.   
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By contrast, if we know more about how a change comes about, we might be 
able to identify alternative superior strategies that are more efficient in triggering 
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a change process.  In particular, as we look back to think about how the gap 
between clinical effectiveness observed under research conditions may be 
effectively translated to ordinary daily practice, knowing about the mechanisms of 
change may help us selectively to guard features that by should not be diluted 
whilst being more relaxed about others that contribute to research vigour but not 
therapeutic efficacy.   
 
Understanding mechanisms better will also help us to pinpoint moderators of 
treatment effectiveness.  As clinicians we know that even the best approach 
doesn’t work for everyone.  But other than a few rules of thumb or truths passed 
down from our teachers, at the start of a treatment we have few ideas about what 
the indicators might be that suggest whether it is likely to work.  Inexperienced 
therapists may often be as or more effective with certain chronic patients (e.g. 
Brown, Lambert, Jones, & Minami, 2005) because they do not have the 
experience that would tell them that their effort is likely to be futile.   
 
Finally, the effectiveness research of the past 50 years, particularly the 
randomized controlled trials, have shown us that psychotherapy is causal in 
bringing about change.  But demonstrating causation is but an illusion of 
explanation and a pernicious illusion at that.  It gives rise to superstitious 
behaviour like Skinner’s pigeons; rather than understanding how our treatments 
work, we merely repeat exactly the behaviors that led to the positive outcomes.  
In the UK we are involved in a nationwide trial of multi-systemic therapy 
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(Henggeler, Clingempeel, Brondino, & Pickrel, 2002) where enormous financial 
and human effort is being expended to replicate the intervention exactly as it was 
carried out in the United States at the Medical University of South Carolina.  This 
is a futile and wasteful effort which is necessary only because of our ignorance of 
mechanisms of therapeutic action.   
 
However, not only experimental studies but also observational studies are 
misleading in terms of identifying the effective components of treatments.  There 
is the legend of the therapeutic alliance, still frequently taught in (k)night schools.  
It is often claimed that the therapeutic alliance is a mediator and mechanism of 
therapeutic change since the stronger the alliance, the greater the change 
observed (Klein et al., 2003).  Correlational studies also show that alliance at the 
beginning of treatment predicts improvement in symptoms at the end (Cloitre, 
Chase Stovall-McClough, Miranda, & Chemtob, 2004).  Do we need any more 
evidence to prove that it is the good relationship with the therapist that cures?  
More recent research that contrasted the outcome of patients with a number of 
therapists found that indeed differences between the effectiveness of therapists 
could be predicted by the strength of alliance they were likely to form with their 
patients (Baldwin, Wampold, & Imel, 2007) but differences in outcome between 
patients with the same therapist were unrelated to therapeutic alliance.   
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If therapeutic alliance was the mechanism of change, then I would expect to do 
better with patients with whom I form a good alliance than those with whom my 
alliance is relatively poor.  This turns out spectacularly not to be the case.  So the 
ability to form an alliance does mark out our more talented therapists but what it 
is that they do more or less of that makes them more or less effective still 
remains a mystery.   
 
Understanding why therapy works will increasingly require an understanding of 
the moderators of therapeutic effectiveness.  Rapidly advancing biological 
research is providing increasingly persuasive evidence that there may be genetic 
limitations on how well therapy can work.  Freud in his last major paper ‘Analysis 
Terminable and Interminable’ seemed to be acutely aware of the limitations of his 
technique, although he might understandably have misperceived some of the 
processes involved.  Six years ago, in a widely quoted study, Avshalom Caspi 
and Terri Moffitt showed that the association between the number of stressful life 
events an individual experienced between 21 and 26 years and the probability of 
depression, suicidal ideation and suicide attempts was moderated by the 5HTT 
genotype (Caspi et al., 2003).  Only those who had two of the short alleles of this 
genotype were likely to respond to four life events with increased suicidal 
ideation.  The association between life events and suicidal ideation of those with 
two long alleles was completely absent.   
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This area of research has become a minor cottage industry, although many 
geneticists are appropriately skeptical about it (Risch et al., 2009).  The most 
challenging finding, to me as an attachment theorist, is the report from 
Kochanska’s laboratory which demonstrated that maternal sensitivity predicted 
infant security of attachment as it is supposed to only in infants with the short 
allele of the 5HTT genotype (Barry, Kochanska, & Philibert, 2008).  Infants with 
the long allele were equally likely to be secure regardless of maternal sensitivity.  
Along similar lines but with older children, Kaufman reported an elegant study 
showing that the depressogenic effects of maltreatment could be mitigated by 
social support in individuals with the short allele of the 5HTT gene (Kaufman et 
al., 2004).   
 
The hypothesis which cries out to be tested is that individuals whose depression 
is more likely to be associated with life events, as their serotonin transported 
gene marks them out to be environmentally sensitive, are also more likely to 
benefit from an environmental intervention such as psychotherapy.  There is 
evidence indicative of the appropriateness of this way of thinking from those 
working on an attachment-based intervention to promote positive parenting and 
sensitive discipline.  In this study, where parents of toddlers with externalizing 
behavioural problems were given video-feedback and other attachment theory 
guided interventions, the children benefitted if they had the 7-repeat allele on the 
DRD4 gene (Bakermans-Kranenburg, Van, Pijlman, Mesman, & Juffer, 2008).   
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The moral here is not that psychotherapy should not be offered to people without 
this or that allele, but rather that the mechanism by which therapy  
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achieves its effect may be quite different for these constitutionally distinguishable 
groups of individuals.  If we choose to ignore the reality of these differences in 
our clinical work, future generations are likely to judge this decision as unethical 
and unjustifiable and potentially as an indication of self serving attitude.   
 
Conclusion 
 
The moral of this long tale is that science is good for practice.  Research is there 
not simply to defend the boundaries of our existing domains, but to help us 
deliver the forms of care which are best for our patients.  To do this we have to 
understand better what causal mechanisms play a role in achieving patient 
benefit and also what circumstances can interfere with a treatment working.  
However, the flow of information should not be one way.  Science, particularly 
neuroscience, will give us better ideas about how we can help our patients in 
more differentiated ways as it evolves.   
 
But practice is also excellent for science.  Practice has to tell researchers where 
knowledge is most needed and to ensure that science is firmly grounded in 
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everyday clinical care.  Best evidence is only meaningful if used in proper 
argumentation.  Argumentation is only meaningful if based on the best evidence 
in its building blocks.  Jules Henri Poincaré wrote: “science is built up with facts 
as a house is with stone, but a collection of facts is no more a science than a 
heap of stones is a house”. 
 
Thus ends my story of research in the land of psychotherapy.  But I have been 
telling this story for long enough to know that arguments are persuasive only 
when they reach those parts of the brain where emotional significance is stored.  
So here is an observational study with personal significance for all in this room.  
Jeffery (2001) collected mortality rates for three groups of white men as a 
function of age.  The sobering cumulative curve shows a positively accelerating 
trend for white males after the age of fifty.  Medical training clearly impacts with a 
strong deceleration, but when we plot mortality rate of psychoanalysts along the 
same axis it is self evident that psychoanalysis is highly efficacious and 
recommends itself as a treatment of choice for life!  
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